Despite challenges, new advances in stem cell biology and genetic engineering show potential for better cell replacement therapies, say experts in a special supplement to JPD
Cell replacement may play an increasing role in alleviating the motor symptoms of Parkinson’s disease (PD) in future. Writing in an open access special supplement to the Journal of Parkinson’s Disease, experts describe how newly developed stem cell technologies could be used to treat the disease and discuss the great promise, as well as the significant challenges, of stem cell treatment.
The most common PD treatment today is based on enhancing the activity of the nigro-striatal pathway in the brain with dopamine-modulating therapies, thereby increasing striatal dopamine levels and improving motor impairment associated with the disease. However, this treatment has significant long-term limitations and side effects. Stem cell technologies show promise for treating PD and may play an increasing role in alleviating at least the motor symptoms, if not others, in the decades to come.
“We are in desperate need of a better way of helping people with PD. It is on the increase worldwide. There is still no cure, and medications only go part way to fully treat incoordination and movement problems,” explained co-authors Claire Henchcliffe, MD, DPhil, from the Department of Neurology, Weill Cornell Medical College, and Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; and Malin Parmar, PhD, from the Wallenberg Neuroscience Center and Lund Stem Cell Center, Lund University, Lund, Sweden. “If successful, using stem cells as a source of transplantable dopamine-producing nerve cells could revolutionize care of the PD patient in the future. A single surgery could potentially provide a transplant that would last throughout a patient’s lifespan, reducing or altogether avoiding the need for dopamine-based medications.”
The authors have analyzed how newly developed stem cell technologies could be used to treat PD, and how clinical researchers are moving very quickly to translate this technology to early clinical trials. In the past, most transplantation studies in PD used human cells from aborted embryos. While these transplants could survive and function for many years, there were scientific and ethical issues: fetal cells are in limited supply, and they are highly variable and hard to quality control. Only some patients benefited, and some developed side effects from the grafts, such as uncontrollable movements called dyskinesias.
Recent strides in stem cell technology mean that quality, consistency, activity, and safety can be assured, and that it is possible to grow essentially unlimited amounts of dopamine-producing nerve cells in the laboratory for transplantation. This approach is now rapidly moving into initial testing in clinical trials. The choice of starting material has also expanded with the availability of multiple human embryonic stem cell lines, as well as the possibilities for producing induced pluripotent cells, or neuronal cells from a patient’s own blood or skin cells. The first systematic clinical transplantation trials using pluripotent stem cells as donor tissue were initiated in Japan in 2018.
“We are moving into a very exciting era for stem cell therapy,” commented Dr. Parmar. “The first-generation cells are now being trialed and new advances in stem cell biology and genetic engineering promise even better cells and therapies in the future. There is a long road ahead in demonstrating how well stem cell-based reparative therapies will work, and much to understand about what, where, and how to deliver the cells, and to whom. But the massive strides in technology over recent years make it tempting to speculate that cell replacement may play an increasing role in alleviating at least the motor symptoms, if not others, in the decades to come.”
“With several research groups, including our own centers, quickly moving towards testing of stem cell therapies for PD, there is not only a drive to improve what is possible for our patients, but also a realization that our best chance is harmonizing efforts across groups,” added Dr. Henchcliffe. “Right now, we are just talking about the first logical step in using cell therapies in PD. Importantly, it could open the way to being able to engineer the cells to provide superior treatment, possibly using different types of cells to treat different symptoms of PD like movement problems and memory loss.”
“This approach to brain repair in PD definitely has major potential, and the coming two decades might also see even greater advances in stem cell engineering with stem cells that are tailor-made for specific patients or patient groups,” commented Patrik Brundin, MD, PhD, Van Andel Research Institute, Grand Rapids, MI, USA, and J. William Langston, MD, Stanford Udall Center, Department of Pathology, Stanford University, Palo Alto, CA, USA, Editors-in-Chief of the Journal of Parkinson’s Disease. “At the same time, there are several biological, practical, and commercial hurdles that need circumventing for this to become a routine therapy.”
The Latest on: Stem cell technologies
via Google News
The Latest on: Stem cell technologies
- Global Stem Cell market forecast to 2023 available in new report on February 18, 2019 at 1:40 pm
The stem cell market is segmented based on the treatment mode, cell types, applications, and technology. Treatment mode is segmented into allogeneic and autologous stem cell therapy. The cells type se... […]
- CRISPR technology creates pluripotent stem cells that are 'invisible' to the immune system on February 18, 2019 at 10:17 am
UC San Francisco scientists have used the CRISPR-Cas9 gene-editing system to create the first pluripotent stem cells that are functionally "invisible" to the immune system, a feat of biological engine... […]
- Stem Cell Therapy Market Report 2019-2024: Analysis Top Key Players Celgene, Mesoblast, Vericel Corporation, Stemcell Technologies on February 18, 2019 at 4:20 am
Selbyville, DE -- (SBWIRE) -- 02/18/2019 -- USA is a huge market, and the total sum of the industry is more than 24 Million US dollars in 2014. At the same time, this industry continuously increases, ... […]
- At 17.8% CAGR, Cell Expansion Technologies Market Size is Expected to Exhibit 24300 million by 2023 on February 17, 2019 at 10:51 pm
Which among these companies - Becton, Dickinson, GE Healthcare, Thermo Fisher Scientific Inc., Corning Inc, Danaher Corp, Merck Millipore, Terumo BCT, STEMCELL Technologies, Sigma-Aldrich Corp, Milten... […]
- New Report of Stem Cell Media Market Overview, Manufacturing Cost Structure Analysis, Growth Opportunities by 2025 on February 15, 2019 at 12:05 am
Market competition is intense. Thermo Fisher, STEMCELL Technologies, Merck Millipore, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; with th... […]
- Newly developed stem cell technologies show promise for treating PD patients on February 14, 2019 at 11:48 pm
Despite challenges, new advances in stem cell biology and genetic engineering show potential for better cell replacement therapies, say experts in a special supplement to the Journal of Parkinson's Di... […]
- Newly Developed Stem Cell Technologies Could Treat Parkinson's Disease: Here's How on February 14, 2019 at 9:56 pm
Newly developed stem cell technologies show promise for treating Parkinson's disease (PD), reports a new study. The findings of the study are published in the Journal of Parkinson's Disease. Cell repl... […]
- Can we repair the brain? The promise of stem cell technologies for treating Parkinson's disease on February 14, 2019 at 9:51 am
Cell replacement may play an increasing role in alleviating the motor symptoms of Parkinson's disease (PD) in future. Writing in a special supplement to the Journal of Parkinson's Disease, experts ... […]
- Global Mesenchymal Stem Cells Industry on February 13, 2019 at 1:39 pm
Stemcell Technologies Inc. (Canada) Stemedica Cell Technologies, Inc. (USA) Thermo Fischer Scientific, Inc. (USA) Vitro Biopharma (USA) 7.2 Product Launches RoosterBio Launches CliniControl™ (CC) Prod... […]
- Korean biotechs snatch U.S. stem cell manufacturing facility on February 13, 2019 at 9:00 am
SCM has a patent for immune disease-specific, next-generation stem cell manufacturing technology. Genexine says it is a clinical stage biotech working in immunotherapeutics and novel long-acting biolo... […]
via Bing News